Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference
02 April 2019 - 10:30PM
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has accepted an
invitation to participate in the H.C. Wainwright Global Life
Sciences Conference (April 7-9 in London). Conatus senior
management will conduct a series of scheduled meetings with
investment professionals and present a company overview on Tuesday,
April 9, 2019, from 10:30 a.m. to 10:50 a.m. BST (5:30 a.m. to 5:50
a.m. EDT). A webcast of the presentation will be available live and
archived in the Investors section of the Conatus website at
www.conatuspharma.com.
About Conatus PharmaceuticalsConatus is a
biotechnology company focused on the development and
commercialization of novel medicines to treat chronic diseases with
significant unmet need. In collaboration with Novartis, Conatus is
developing its lead in-licensed compound, emricasan, for the
treatment of patients with NASH-driven chronic liver diseases.
Conatus is independently developing its lead internally developed
compound, CTS-2090, for the treatment of patients with chronic
diseases involving inflammasome pathways. For additional
information, please visit www.conatuspharma.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. All
statements other than statements of historical facts contained in
this press release are forward looking statements. In some
cases, you can identify forward-looking statements by terms such as
“may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplates,” “believes,”
“estimates,” “predicts,” “potential” or “continue” or the negative
of these terms or other similar expressions. These
forward-looking statements speak only as of the date of this press
release and are subject to a number of risks, uncertainties and
assumptions, including those risks described in the company’s prior
press releases and in the periodic reports it files with the
Securities and Exchange Commission. The events and
circumstances reflected in the company’s forward-looking statements
may not be achieved or occur and actual results could differ
materially from those projected in the forward-looking statements.
Except as required by applicable law, the company does not plan to
publicly update or revise any forward-looking statements contained
herein, whether as a result of any new information, future events,
changed circumstances or otherwise.
CONTACT: Alan EngbringConatus
Pharmaceuticals Inc.(858) 376-2637aengbring@conatuspharma.com
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Apr 2024 to May 2024
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Conatus Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles